Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Pfizer announced it is ending its development of a once-daily weight-loss pill treatment for obesity. It comes after a participant in one of the trials experienced a possible drug-induced liver injury ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to ...